Omari 25

Recommended dosage: The recommended dose of Omarigliptin is 25 mg once weekly as monotherapy or as add-on therapy for optimisation of glycemic control. If patient misses a dose, advice to take the missed dose as soon as possible and then follow the regular weekly dosing schedule. Never take two doses at one time. Renal impairment: The dosage in patients with severe renal dysfunction or with end-stage renal failure or in those requiring hemodialysis or peritoneal dialysis should be according to the following: Severe end-stage kidney failur- Men: CrCl>1.9: 12.5 mg once a week Women: CrCl >1.4: 12.5 mg once a week. Use in children and adolescents: Safety and efficacy of omarigliptin in children and adolescents have not been established. * Take medicine as per doctor's advice.

Omarigliptin tablets should be taken in oral route.

Drug interaction with medication: Omarigliptin interacts with metformin, glimepiride, oral contraceptives and atorvastatin. Other anti-diabetic drugs (in particular, insulin preparation or sulfonylurea) should be used with caution in combination with omarigliptin, as they may cause hypoglycemia. Precaution must be taken with drugs that enhances the hypoglycemic action (3-blockers, salicylic acid agents, monoamine oxidase inhibitors). Blood glucose level should be carefully monitored when using drugs that attenuate the hypoglycemic action (adrenaline, adrenocorticotropic hormone, thyroid hormone).

Omarigliptin is contraindicated in patients with hypersensitivity to omarigliptin or any other component of this product. It is also contraindicated in severe ketosis, diabetic coma or precoma in type 1 diabetes patients. Omarigliptin is contraindicated in severe infection in which glycemic control is desired by insulin injection, before and after surgery and in patients with severe trauma.

The adverse effects of omarigliptin are generally well tolerated. The most common side effects are nasopharyngitis, hypoglycemia, constipation, diarrhea, gastrointestinal problem, skin and subcutaneous tissue disorders.

Omarigliptin should be administered with caution in following patients or conditions which might cause low blood sugar such as pituitary dysfunction or adrenal insufficiency; malnutrition, starvation, irregular dietary intake, lack of dietary intake or debilitated state; intense muscle movement; excessive alcohol intake and elder person. Caution should be taken in patients engaged in aerial work or operation of an automobile.

No data is available regarding overdose of omarigliptin. In the event of overdosage, supportive care is advised.

Store in a cool (below 30°C) & dry place protected from the light. Keep away from the reach of children.